Technical Analysis for PRLD - Prelude Therapeutics Incorporated

Grade Last Price % Change Price Change
C 4.65 -1.90% -0.09
PRLD closed down 1.9 percent on Monday, March 18, 2024, on 57 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
20 DMA Support Bullish -1.90%
Pocket Pivot Bullish Swing Setup -1.90%
Reversal New Highs Setup Bullish Swing Setup -1.90%
Stochastic Reached Overbought Strength -1.90%
Outside Day Range Expansion -1.90%
Overbought Stochastic Strength -1.90%
Gapped Down Weakness -1.90%
Earnings Movers Other 4.26%

   Recent Intraday Alerts

Alert Time
Up 3% about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Up 2% about 12 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
Down 2 % about 16 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prelude Therapeutics Incorporated Description

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Protein Kinase Inhibitor Glioblastoma Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor

Is PRLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.565
52 Week Low 1.66
Average Volume 79,585
200-Day Moving Average 3.69
50-Day Moving Average 3.75
20-Day Moving Average 4.26
10-Day Moving Average 4.38
Average True Range 0.39
RSI (14) 60.32
ADX 35.26
+DI 27.37
-DI 12.51
Chandelier Exit (Long, 3 ATRs) 3.75
Chandelier Exit (Short, 3 ATRs) 4.56
Upper Bollinger Bands 4.77
Lower Bollinger Band 3.75
Percent B (%b) 0.89
BandWidth 23.97
MACD Line 0.25
MACD Signal Line 0.22
MACD Histogram 0.0253
Fundamentals Value
Market Cap 195.21 Million
Num Shares 42 Million
EPS -2.15
Price-to-Earnings (P/E) Ratio -2.16
Price-to-Sales 0.00
Price-to-Book 0.62
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.13
Resistance 3 (R3) 5.17 5.05 5.05
Resistance 2 (R2) 5.05 4.93 5.03 5.02
Resistance 1 (R1) 4.85 4.85 4.79 4.81 5.00
Pivot Point 4.73 4.73 4.70 4.71 4.73
Support 1 (S1) 4.53 4.61 4.47 4.49 4.30
Support 2 (S2) 4.41 4.53 4.39 4.28
Support 3 (S3) 4.21 4.41 4.25
Support 4 (S4) 4.17